Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Europe and Israel or involving organisations from these countries.

Total search results: 7968 | Ordered by Date (descending)
1 2 3 ... 78 79 80  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Psyros Diagnostics–Prolight Diagnostics: investment, 202201 acquisition merger up to SEK65m in new shares with SEK45.5m upfront + SEK19m.5m milestones 2022-01-20
Altos Labs–SEVERAL: investment, 202201 launch with $3b fully commited from founders + investors 2022-01-19
Engitix–SEVERAL: investment, 202201 financing round Series A $54m co-led by Netherton Investments (Mike Platt) + Dompé 2022-01-19
Pneumagen–Scotland (govt): investment, 202201 financing round totalling Ł3.8m incl existing + co-lead investor Scottish Enterprise 2022-01-19
Pneumagen–SEVERAL: investment, 202201 financing round Ł3.8m co-led by existing investors Thairm Bio + Scottish Enterprise 2022-01-19
Pneumagen–Thairm Bio: investment, 202201 financing round totalling Ł3.8m incl existing + co-lead investor Thairm Bio 2022-01-19
Prolab Instruments–Bruker: investment, 202201 acquisition €na of Prolab Instruments Gmbh by Bruker 2022-01-19
Zogenix–UCB: investment, 202201– cash tender offer $1.76b at $26/share plus $135.7m CVR milestones ANNOUNCED 2022-01-19
Labiotech.eu–Inova Software: investment, 202201 acquisition by Inova 2022-01-18
Oribiotech–Image Box: public relations, 202201 service existent by Image Box Communications 2022-01-18
Oribiotech–Novalis LifeSciences: investment, 202201 financing round Series B totalling $100m incl new + lead investor Novalis LS Investments II 2022-01-18
Oribiotech–Puhua Capital: investment, 202201 financing round Series B totalling $100m incl new + co-investor Puhua Capital 2022-01-18
Oribiotech–SEVERAL: investment, 202201 financing round Series B $100m led by Novalis LifeSciences 2022-01-18
PreOmics–Bruker: investment, 202201 acquisition €na of shares of HTGF + Think.Health Ventures + certain business angels by Bruker 2022-01-18
PreOmics–Bruker: investment, 202201 Series B investment €13.5m from Bruker tog w secondary transaction making Bruker majority shareholder 2022-01-18
ProtaGene–Ampersand: investment, 202201 existent portfolio company after merger/acquisition of PPS GmbH + BioAnalytix + GeneWerk GmbH in 7/21 2022-01-12
Rockefeller Univ–Lumicks: microscope, 202201 supply of Quadrupole C-Trap system to lab of Prof Michael O’Donnell 2022-01-12
Temedica–MC Services: public relations, 202201 service existent PR + IR by MC Services 2022-01-12
Creoptix–Spectris: investment, 202201 acquisition of Creoptix AG by Malvern Panalytical 2022-01-11
Pantherna Therapeutics–High-Tech Gründerfonds: investment, 202201 follow-on financing round totalling €4m incl existing + co-lead investor HTGF 2022-01-11
Pantherna Therapeutics–PERSON: investment, 202201 follow-on financing round totalling €4m incl existing + co-lead investor Riesner Verwaltungs GmbH 2022-01-11
Pantherna Therapeutics–SEVERAL: investment, 202201 follow-on financing round €4m led by existing investors Detlev Riesner + HTGF 2022-01-11
RoslinCT–GHO Capital: investment, 202201 (majority?) investment by GHO Capital Partners LLP 2022-01-11
Scitara–Scott Partnership: public relations, 202201 service existent by Scott PR 2022-01-11
BioNTech–Crescendo Biologics: antibody technology, 202201–202512 collab ww up to $790m + royalties using Humabody VH platform for BioNTech targets 2022-01-10
Crescendo Biologics–BioNTech: investment, 202201 equity investment €na as part of €40m collab upfront payment with cash + equity investment 2022-01-10
Exelead–Merck (DE): investment, 202201– acquisition $760m in cash by Merck ANNOUNCED 2022-01-06
BioNTech–Pfizer: investment, 202201 equitiy investment $150m by Pfizer in connection with shingles vaccine collaboration 2022-01-05
Pfizer–BioNTech: mRNA-based vaccines, 202201– collab developm $50m net cash upfront shingles vaccine with shared development cost + profits 2022-01-05
PhoreMost–Polaris Quantum Biotech: cancer drug discovery, 202201– collab r+d using Tachyon quantum computing platform with Siteseeker platform 2022-01-05
Sound Bioventures–Denmark (govt): investment, 202201 1st closing of 1st fund totalling €110m incl investor Vćkstfonden 2022-01-04
Sound Bioventures–EU (govt): investment, 202201 1st closing of 1st fund totalling €110m incl investor EIF unde EGF 2022-01-04
Sound Bioventures–Novo Group: investment, 202201 1st closing of 1st fund totalling €110m incl investor Novo Holdings 2022-01-04
Sound Bioventures–PERSON: investment, 202201 1st closing of 1st fund totalling €110m incl founding partners C Breum + J Kördel + B Mukhopadhyay 2022-01-04
Sound Bioventures–Ramsbury Invest: investment, 202201 1st closing of 1st fund totalling €110m incl investor Ramsbury Invest 2022-01-04
Sound Bioventures–SEVERAL: investment, 202201 first closing of €110m Sound Bioventures Fund I AB 2022-01-04
Sound Bioventures–Sweden (govt): investment, 202201 1st closing of 1st fund totalling €110m incl investor Saminvest 2022-01-04
ALS Automated Lab Solutions–Sartorius: investment, 202201–2026 acquisition of 62.5% share in ALS with remaining share to be acquired in 2026 2022-01-03
Evolva–Nice & Green: credit, 202112–202312 convertible notes financing with incremental lines up to max of CHF12m principal amount 2021-12-27
Antigon–Analis: investment, 202112 financing round totalling €1.5m incl new investor Analis SA 2021-12-22
Antigon–BeAngels: investment, 202112 financing round totalling €1.5m incl existing investor Be Angels 2021-12-22
Antigon–HTP Europe: investment, 202112 financing round totalling €1.5m incl new investor HTP Europe 2021-12-22
Antigon–Sambrinvest: investment, 202112 financing round totalling €1.5m incl existing investor Sambrinvest 2021-12-22
Antigon–SEVERAL: investment, 202112 financing round €1.5m with Sambrinvest + BeAngels + Analis + HTP Europe 2021-12-22
Gyroscope Therapeutics–Novartis: investment, 202112– acquisition $800m upfront + $700m milestones by Novartis ANNOUNCED 2021-12-22
Sorriso Pharmaceuticals–Arix Bioscience: investment, 202112 financing round Series A totalling $31m incl $13m (26%stake) from co-lead investor Arix 2021-12-22
Sorriso Pharmaceuticals–SEVERAL: investment, 202112 financing round Series A $31m co-led by NEA + Arix Bioscience plc 2021-12-22
21st.BIO–Novo Group: industrial biotech production technology, 202112– co-excl license for technology platform from Novozymes 2021-12-21
21st.BIO–Novo Group: investment, 202112 investment €86m by Novo Holdings 2021-12-21
Alesta Therapeutics–Thuja Capital: investment, 202112 existent investment of Thuja Capital Healthcare Fund III 2021-12-21
Amunix Pharmaceuticals–Sanofi: investment, 202112– acquisition $1b upfront + $225m milestones ANNOUNCED 2021-12-21
EsoBiotec–Thuja Capital: investment, 202112 existent investment of Thuja Capital Healthcare Fund III 2021-12-21
Protein Metrics–Insightful Science: investment, 202112 acquisition of Protein Metrics by Insightful Science 2021-12-21
Thuja Capital–SEVERAL: investment, 202112 final closing of Thuja Capital Heathcare Fund III at €76m incl investor EIF 2021-12-21
Chord Therapeutics–Merck (DE): investment, 202112– acquisition of Chord by Merck KGaA from sole investor Omega Funds 2021-12-20
Genenta Science–LifeSci: public relations, 202112 service existent IR by LifeSci Advisors 2021-12-17
Genenta Science–SEVERAL: investment, 202112 direct offering $8.28m of 720.1k ordinary shares for subscription by exisiting shareholders at $11.5/share 2021-12-17
NorthSea Therapeutics–BioGeneration Ventures: investment, 202112 financing round Series C totalling $80m incl existing + co-investor BGV 2021-12-17
NorthSea Therapeutics–Forbion: investment, 202112 financing round Series C totalling $80m incl existing + co-lead investor Forbion 2021-12-17
NorthSea Therapeutics–Hercules Capital: investment, 202112 financing round Series C totalling $80m incl new + co-investor Hercules Capital 2021-12-17
NorthSea Therapeutics–New Science Ventures: investment, 202112 financing round Series C totalling $80m incl existing + co-investor New Science 2021-12-17
NorthSea Therapeutics–Novo Group: investment, 202112 financing round Series C totalling $80m incl existing + co-investor Novo Seeds 2021-12-17
NorthSea Therapeutics–OTHER: investment, 202112 financing round Series C totalling $80m incl new + co-investor large managed care organisation 2021-12-17
NorthSea Therapeutics–SEVERAL: investment, 202112 financing round Series C $80m co-led by Ysios Capital + Forbion Growth 2021-12-17
NorthSea Therapeutics–Sofinnova: investment, 202112 financing round Series C totalling $80m incl existing + co-investor Sofinnova 2021-12-17
NorthSea Therapeutics–VenBio: investment, 202112 financing round Series C totalling $80m incl existing + co-investor VenBio 2021-12-17
NorthSea Therapeutics–Ysios Capital: investment, 202112 financing round Series C totalling $80m incl new + co-lead investor Ysios Capital 2021-12-17
Anaveon–Cowen: investment, 202112 financing round Series B totalling CHF110m incl new + co-investor Cowen Healthcare Investments 2021-12-16
Anaveon–Forbion: investment, 202112 financing round Series B totalling CHF110m incl new + lead investor Forbion 2021-12-16
Anaveon–JW Communications: public relations, 202112 service existent by JW Communications 2021-12-16
Anaveon–Novartis: investment, 202112 financing round Series B totalling CHF110m incl existing + co-investor Novartis Venture Fund 2021-12-16
Anaveon–Pfizer: investment, 202112 financing round Series B totalling CHF110m incl new + co-investor Pifzer Ventures 2021-12-16
Anaveon–Pontifax: investment, 202112 financing round Series B totalling CHF110m incl new + co-investor Pontifax 2021-12-16
Anaveon–SEVERAL: investment, 202112 financing round Series B CHF110m with new + lead investor Forbion 2021-12-16
Anaveon–Syncona: investment, 202112 financing round Series B totalling CHF110m incl existing + co-lead investor Syncona 2021-12-16
Aptamer Group–Consilium: public relations, 202112 service existent by Consilium Strategic Communications 2021-12-16
Aptamer Group–SEVERAL: investment, 202112 IPO Ł10.8m net Ł9.1m with 9.2m new ordinary shares at Ł1.15/share 2021-12-16
Argobio–GeneCode: GDNF mimetics, 202112– collab development with up to €3m funding for incubation phase by Argobio to incorporate new biotech company 2021-12-16
Bioqube Ventures–Metrion Biosciences: drug discovery services, 202112– collab project to identify ion channel inhibtors for autoimmune diseases 2021-12-16
Bioqube Ventures–Optimum Strategic Communications: public relations, 202112 service existent by Optimum 2021-12-16
Biosero–Bico: investment, 202112– acquisition up to $165m in cash + shares by Bico 2021-12-16
Evotec–Gates Foundation: grant, 202112– grant $18m for drug r+d in area of women’s health + contraceptive technology 2021-12-16
Synerkine Pharma–Flerie Invest: investment, 202112 financing round Series A extension totalling €3.5m incl new + lead investor Flerie Invest 2021-12-16
Synerkine Pharma–SEVERAL: investment, 202112 financing round Series A extension €3.5m from Flerie Invest + Thuja Capital + Utrecht Holdings 2021-12-16
Synerkine Pharma–Thuja Capital: investment, 202112 financing round Series A extension totalling €3.5m incl existing + co-investor Thuja Capital 2021-12-16
Synerkine Pharma–Univ Utrecht: investment, 202112 financing round Series A extension totalling €3.5m incl existing + co-investor Utrecht Holdings 2021-12-16
Depixus–Arix Bioscience: investment, 202112 financing round Series A totalling €30.6m incl existing + co-investor Arix Bioscience 2021-12-15
Depixus–Casdin Capital: investment, 202112 financing round Series A totalling €30.6m incl new + co-investor Casdin Capital 2021-12-15
Depixus–France (govt): investment, 202112 financing round Series A totalling €30.6m incl new + co-lead investor PSIM Fund managed by Bpifrence 2021-12-15
Depixus–Lansdowne Partners: investment, 202112 financing round Series A totalling €30.6m incl new + co-lead investor Lansdowne Partners 2021-12-15
Depixus–SEVERAL: investment, 202112 financing round Series A €30.6m co-led by Lansdowne Partners + PSIM Fund (Bpifrance) 2021-12-15
Lonza–Agilent: analytical instruments, 202112– strategic alliance to integrate analytical technologies in Cocoon cell therapy production platform 2021-12-15
Biogazelle–CellCarta: investment, 202112 acquisition of Biogazelle by CellCarta 2021-12-14
BMS–Immatics: TCR Bispecific, 202112– license ww excl $150m upfront + $770m milestones + royalties to IMA401 programme 2021-12-14
Novartis–Molecular Partners: DARPins, 202112– collab $20m upfront + $560m milestones + royalties license to develop + manuf + commerc DARPin-RLTs 2021-12-14
Ryvu Therapeutics–LifeSci: public relations, 202112 service existent IR by LifeSci Advisors 2021-12-14
Sirius Medical–SEVERAL: investment, 202112 financing round Series A 2nd closing €na with BOM Brabant Ventures + Holland Capital et al 2021-12-14
Vifor Pharma–CSL: investment, 202112– cash tender offer CHF10.9b ($11.7b) at CHF167/share ANNOUNCED 2021-12-14
Memo Therapeutics–Switzerland (govt): grant, 202112– FOPH grant CHF10.5m for clinical developm of SARS-CoV-2 antibody COVAB 36 2021-12-13
Corteria Pharmaceuticals–Invivo Capital: investment, 202112 seed financing round totalling €12m incl co-investor Invivo Capital 2021-12-09
1 2 3 ... 78 79 80  next pagenext page



Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

» top